You are here: Industry Insights > SNG001

News List

Synairgen Partners with Ashfield Engage to Support the Commercialization of SNG001 contractpharma
January 06, 2022
Aims to bring innovative potential treatment to COVID-19 patients.
Bharat Biotech’s Covaxin may provide Covid-19 immunity for 12 months pharmaceutical-technology
February 18, 2021
All India Institute of Medical Sciences (AIIMS) said that Bharat Biotech’s Covid-19 vaccine, Covaxin, may provide immunity against the disease for nine to 12 months, as per the mathematical calculations.
Synairgen begins large-scale trial of inhaled COVID-19 treatment pharmatimes
January 14, 2021
Southampton, UK-headquartered company Synairgen has treated the first patient in the UK as part of a global Phase III trial evaluating its inhaled COVID-19 treatment SNG001 in hospitalised patients.
UK study shows SNG001 aids in faster Covid-19 recovery pharmaceutical-technology
November 17, 2020
The University of Southampton in the UK has published the results from a clinical trial of an inhaled form of interferon beta-1a, SNG001, which reduced chances of hospitalised Covid-19 patients developing severe disease or death due to infection.
Inhaled interferon beta therapy shows promise in COVID-19 trial europeanpharmaceuticalreview
July 21, 2020
SNG001 diminished the risk of COVID-19 patients developing severe symptoms, reduced breathlessness and improved recovery rates.
Synairgen's SNG001 shows strong promise in COVID-19 trial pharmatimes
July 20, 2020
Southampton, UK-based Synairgen has announced positive results from a clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients.
Researchers to trial SNG001 therapeutic in COVID-19 patients europeanpharmaceuticalreview
March 24, 2020
Hospitalised patients in the UK will inhale the interferon beta 1a (IFN-β) formulation or a placebo to see if SNG001 is effective against the COVID-19 coronavirus.